In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
In the latest session, BioAtla Inc (NASDAQ: BCAB) closed at $2.64 down -2.58% from its previous closing price of $2.71. In other words, the price has decreased by -$2.58 from its previous closing price. On the day, 1.04 million shares were traded. BCAB stock price reached its highest trading level at $2.855 during the session, while it also had its lowest trading level at $2.5901.
Ratios:
For a deeper understanding of BioAtla Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.11 and its Current Ratio is at 4.11. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, JMP Securities on September 15, 2022, initiated with a Mkt Outperform rating and assigned the stock a target price of $17.
On May 05, 2022, Credit Suisse Downgraded its rating to Neutral which previously was Outperform and also lowered its target price recommendation from $35 to $5.
On March 21, 2022, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $25.H.C. Wainwright initiated its Buy rating on March 21, 2022, with a $25 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Dec 26 ’23 when MCBRINN SYLVIA bought 4,000 shares for $2.33 per share. The transaction valued at 9,320 led to the insider holds 15,125 shares of the business.
SHORT JAY M PHD bought 50,000 shares of BCAB for $106,910 on Dec 20 ’23. The Chief Executive Officer now owns 1,439,283 shares after completing the transaction at $2.14 per share. On Dec 19 ’23, another insider, STEINMAN LAWRENCE, who serves as the Director of the company, bought 20,000 shares for $2.05 each. As a result, the insider paid 41,048 and bolstered with 38,459 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BCAB now has a Market Capitalization of 127000640 and an Enterprise Value of 17964332.
Stock Price History:
The Beta on a monthly basis for BCAB is 1.27, which has changed by -0.2605042 over the last 52 weeks, in comparison to a change of 0.2704494 over the same period for the S&P500. Over the past 52 weeks, BCAB has reached a high of $4.07, while it has fallen to a 52-week low of $1.24. The 50-Day Moving Average of the stock is -7.75%, while the 200-Day Moving Average is calculated to be 14.45%.
Shares Statistics:
For the past three months, BCAB has traded an average of 608.50K shares per day and 1027820 over the past ten days. A total of 48.08M shares are outstanding, with a floating share count of 38.78M. Insiders hold about 19.39% of the company’s shares, while institutions hold 53.97% stake in the company. Shares short for BCAB as of 1714435200 were 5329887 with a Short Ratio of 8.76, compared to 1711584000 on 5588159. Therefore, it implies a Short% of Shares Outstanding of 5329887 and a Short% of Float of 12.3900004.
Earnings Estimates
The stock of BioAtla Inc (BCAB) is currently being evaluated by 4.0 analysts who are actively contributing to its market rating.On average, analysts expect EPS of -$0.79 for the current quarter, with a high estimate of -$0.71 and a low estimate of -$1.0, while EPS last year was -$0.63. The consensus estimate for the next quarter is -$0.54, with high estimates of -$0.44 and low estimates of -$0.6.
Analysts are recommending an EPS of between -$2.74 and -$2.78 for the fiscal current year, implying an average EPS of -$2.76. EPS for the following year is -$1.93, with 5.0 analysts recommending between -$1.78 and -$2.14.
